{
  "trial_id": "NCT01722578",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Study Methods",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Assignment: Consecutive patients diagnosed to have acute overt HE will be randomized into two groups (group A and B) using sealed opaque envelopes containing computer-generated random numbers.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Masking: Sequentially numbered boxes containing identical LOLA or placebo ampoules, according to the allocation sequence will ensure allocation concealment.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Randomization implementation: Enrollment of patients, assessing eligibility and obtaining informed consent will be carried out by one of the investigators (S.S. Sidhu or O. Goyal, BC Sharma)",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Study Intervention: The patients will be randomized to receive either placebo or LOLA at dose of 30 grams daily, by intravenous infusion over 24 hours.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Laboratory tests: Biochemical tests: Hemogram, blood glucose, liver function tests, prothrombin time, serum electrolytes, blood urea and serum creatinine will be done at baseline, and at 2nd and 5th day of treatment, or earlier if indicated.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Ammonia estimation: Fasting venous ammonia levels will be estimated by using the blood ammonia meter (PocketChem BA) at baseline and then daily for the next 5 days.",
      "label": "met",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients who are terminally ill",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Acute on chronic liver failure",
      "label": "triggers",
      "evidence": ""
    },
    {
      "criterion": "Hepatocellular carcinoma",
      "label": "triggers",
      "evidence": ""
    },
    {
      "criterion": "Wilson's disease as the etiological factor of liver disease",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Advanced cardiac or pulmonary disease",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Presence of underlying chronic renal failure",
      "label": "triggers",
      "evidence": ""
    },
    {
      "criterion": "Neuro-degenerative disease or major psychiatric illness",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Patients on sedatives or antidepressants",
      "label": "triggers",
      "evidence": ""
    }
  ],
  "notes": "The patient has Parkinson's disease, but the study focuses on liver encephalopathy. The patient is not terminally ill, and there is no mention of acute on chronic liver failure, hepatocellular carcinoma, Wilson's disease, advanced cardiac or pulmonary disease, or underlying chronic renal failure. However, the patient does have neuro-degenerative disease (Parkinson's), which may be a concern for the study.",
  "_meta": {
    "topic_id": "41",
    "trial_id": "NCT01722578",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}